LIMN
Liminatus Pharma, Inc. Class A Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.28M
P/E Ratio
—
EPS
$-0.43
Beta
0.50
52W High
$33.66
52W Low
$0.16
50-Day MA
$0.45
200-Day MA
$2.58
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-2.97M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -62.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.06 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $44.88M |
| Float | $29.07M |
| % Insiders | 38.49% |
| % Institutions | 0.71% |
Data last updated: 4/8/2026